Schlidt is the cofounder and managing partner at Palo Santo, a venture capital fund focused exclusively on the advancement of psychedelic therapies for the treatment of mental health disorders and beyond. Based on his own experience with severe depression as a teenager, Schlidt's goal is to steward the most efficacious psychedelic therapies towards FDA approval so that patients may safely, legally, and affordably access these medicines. He has deployed $25 million into 20 companies including Gilgamesh, Journey Clinical and Sensorium.
Show Highlights:
-The potential of psychedelics for mental health treatment.
-Tim's story leading to investment in psychedelics.-Why to practice safe and supervised use of psychedelics in treatment.-Legal and ethical considerations around the use of psychedelics.
-What are challenges in developing psychedelics?-Predicitons for psychedelics in mainstream medicine.
-Psychedelics for therapeutic and personal growth.
Podden och tillhörande omslagsbild på den här sidan tillhör
Dr. Neil Paulvin. Innehållet i podden är skapat av Dr. Neil Paulvin och inte av,
eller tillsammans med, Poddtoppen.
